People: Idenix Pharmaceuticals Inc (IDIX.O)
IDIX.O on Nasdaq
4.06USD
20 May 2013
4.06USD
20 May 2013
Price Change (% chg)
$-0.11 (-2.64%)
$-0.11 (-2.64%)
Prev Close
$4.17
$4.17
Open
$4.17
$4.17
Day's High
$4.28
$4.28
Day's Low
$4.03
$4.03
Volume
1,031,997
1,031,997
Avg. Vol
893,663
893,663
52-wk High
$11.30
$11.30
52-wk Low
$3.21
$3.21
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Thomas Hodgson |
71 | 2012 | Independent Chairman of the Board |
Ronald Renaud |
43 | 2010 | President, Chief Executive Officer, Director |
Daniella Beckman |
33 | 2012 | Chief Financial Officer, Senior Vice President, Treasurer |
David Standring |
61 | 2011 | Executive Vice President, Chief Scientific Officer |
Douglas Mayers |
58 | 2007 | Executive Vice President - Clinical Development, Chief Medical Officer |
Maria Stahl |
41 | 2010 | Senior Vice President, General Counsel, Secretary |
Paul Fanning |
54 | 2007 | Senior Vice President - Human Resources |
Wayne Hockmeyer |
68 | 2002 | Independent Director |
Tamar Howson |
64 | 2010 | Independent Director |
Denise Pollard-Knight |
52 | 2003 | Independent Director |
Michael Wyzga |
57 | 2012 | Independent Director |
Teri Dahlman |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Thomas Hodgson |
Mr. Thomas R. Hodgson is Independent Chairman of the Board of Idenix Pharmaceuticals Inc., since March 01, 2012. Mr. Hodgson, who is retired, served most recently, from September 1990 to January 1999, as president and chief operating officer of Abbott Laboratories, a pharmaceutical company. From 1983 to 1990, Mr. Hodgson served as the president of Abbott International and from 1978 to 1983, Mr. Hodgson served as the president of the Hospital Products Division of Abbott Laboratories. Mr. Hodgson is a director of The Travelers Companies Inc. and has previously served as a director of Intermune, Inc. Mr. Hodgson holds a B.S. from Purdue University, an M.S. from the University of Michigan, an M.B.A. from Harvard Business School and an honorary doctorate degree in engineering awarded by Purdue University. |
Ronald Renaud |
Mr. Ronald C. Renaud, Jr., is President, Chief Executive Officer, Director of Idenix Pharmaceuticals Inc. Mr. Renaud served as chief financial officer and treasurer since June 2007 and as chief business officer since June 2010. Prior to joining Idenix in 2007, Mr. Renaud served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, from February 2006 to May 2007. Mr. Renaud was a senior research analyst and global sector coordinator for JP Morgan Securities from May 2004 until February 2006, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California. |
Daniella Beckman |
Ms. Daniella Beckman is Senior Vice President, Chief Financial Officer and Treasurer of Idenix Pharmaceuticals Inc. She has held these postions since February 2012 and served as vice president, chief financial officer and treasurer from June 2011 to February 2012. From October 2010 to June 2011, Ms. Beckman served as interim chief financial officer and treasurer. Prior to that, Ms. Beckman served as corporate controller from March 2008 to October 2010. From March 2006 to March 2008, Ms. Beckman held positions at Coley Pharmaceutical Group, most recently as corporate controller. Prior to Coley, Ms. Beckman held positions at Biogen Idec from September 2004 through March 2006 as well as PricewaterhouseCoopers LLP from September 2000 through 2004. Ms. Beckman holds a B.A. from Boston University. She is also a Certified Public Accountant, or CPA. |
David Standring |
Dr. David N. Standring, Ph.D., is Executive Vice President, Chief Scientific Officer of Idenix Pharmaceuticals Inc., since February 2011. Previously, Dr. Standring served as executive vice president, biology from December 2007 to February 2011, as senior vice president, biology from March 2006 to December 2007, as vice president, biology from March 2002 to March 2006 and as executive director of biology from September 2000 to March 2002. Prior to joining Idenix, from February 1998 to July 2000, Dr. Standring served as research fellow and then as associate director, virology department at Schering-Plough Research Institute, a division of Schering Plough Corporation, a pharmaceutical company. From November 1994 to January 1998, Dr. Standring served as group leader, hepatitis, virology department at Bristol-Myers Squibb Research Institute. From 1984 to 1994, Dr. Standring was on the faculty of the University of California at San Francisco. Dr. Standring holds a B.A. from St. John’s College, Oxford University and a Ph.D. in Bioorganic Chemistry from Harvard University. |
Douglas Mayers |
Dr. Douglas Mayers, M.D., is Executive Vice President - Clinical Development and Chief Medical Officer of Idenix Pharmaceuticals Inc., since January 8, 2007. Prior to joining Idenix, from May 2001 until January 2007, Dr. Mayers was with Boehringer Ingelheim Pharmaceuticals, Inc., where he served as vice president, therapeutic area of virology and was responsible for the strategic coordination of all HIV and hepatitis clinical trials in phases I through IV. Prior to joining Boehringer Ingelheim, Dr. Mayers conducted clinical trials in HIV research during his seventeen years in the United States Navy and his subsequent three years as the head of infectious diseases with Henry Ford Hospital. Dr. Mayers completed his M.D. at the University of Pennsylvania. |
Maria Stahl |
Ms. Maria D. Stahl is Senior Vice President, General Counsel, Secretary of Idenix Pharmaceuticals nc., since October 2010. Ms. Stahl served as vice president, associate general counsel from February 2008 to November 2009 and as assistant general counsel from February 2007 to February 2008. Prior to rejoining Idenix, Ms. Stahl served as general counsel of Zipcar, Inc., a car sharing company, from November 2009 to October 2010. From February 2005 to February 2007, Ms. Stahl served as vice president, corporate counsel of Capital Crossing Bank. Prior to that, Ms. Stahl was at Wilmer Cutler Pickering Hale and Dorr LLP from 1997 to 2005. Ms. Stahl has a B.A. from Providence College and a juris doctorate from Yale Law School. |
Paul Fanning |
Mr. Paul J. Fanning is Senior Vice President - Human Resources of Idenix Pharmaceuticals Inc. He has held these positions since December 2007 and served as vice president, human resources from March 2004 to December 2007. Prior to joining Idenix, Mr. Fanning was employed by The Foxboro Company and its affiliates from 1984 to 2004, most recently as vice president, human resources at Invensys Process Systems from 2000 to 2004. Mr. Fanning holds an M.B.A. from Babson College and a B.S. from the University of Massachusetts. |
Wayne Hockmeyer |
Dr. Wayne T. Hockmeyer, Ph.D., is Independent Director of Idenix Pharmaceuticals Inc. Dr. Hockmeyer founded MedImmune, Inc., a biotechnology company, in April 1988 and served until October 2000 as its chief executive officer. Dr. Hockmeyer continued to serve as chairman of the board of directors of MedImmune, Inc. until June 2007. From 2002 to 2007, Dr. Hockmeyer served as president of MedImmune Ventures, Inc., a wholly owned subsidiary of MedImmune, Inc. Dr. Hockmeyer also serves as a director of Baxter International, Inc. and GenVec, Inc. and has previously served as a director of Middlebrook Pharmaceutical Corporation. Dr. Hockmeyer was recognized in 1998 by the University of Florida as a Distinguished Alumnus and in 2002 was awarded a Doctor of Science honoris causa from Purdue University. Dr. Hockmeyer holds a B.S. from Purdue University and a Ph.D. from the University of Florida. |
Tamar Howson |
Ms. Tamar D. Howson is Independent Director of Idenix Pharmaceuticals Inc., since March 30, 2010. Ms. Howson is currently acting as a consultant to biotechnology companies. Until recently Ms. Howson was a member of JSB-Partners, a transaction advisory firm serving the life sciences industry. Prior to joining JSB-Partners in 2010, Ms. Howson was executive vice president of business development at Lexicon Pharmaceuticals where she led the company’s partnering and licensing efforts. From 2001 to 2007, Ms. Howson was senior vice president corporate and business development at Bristol Myers Squibb, overseeing mergers and acquisitions, licensing and research collaborations. During 2000 and 2001, Ms. Howson served as a business development and strategy consultant to various biotechnology companies in the United States and in Europe. Ms. Howson was also a senior vice president and director of business development at SmithKline Beecham from 1991 to 2000. Ms. Howson currently acts as interim chief executive officer and a director of S*Bio, a clinical stage oncology company. Ms. Howson also serves on the boards of directors of OXiGENE, Inc., a clinical-stage biopharmaceutical company developing therapeutics to treat cancer and eye diseases, Aradigm Corp., a company developing drugs for respiratory and metabolic diseases and Soligenix Inc., a company developing treatments for transplantation. She previously served as a director of Ariad Pharmaceuticals, SkyePharma, NPS Pharmaceuticals and Targacept. Ms. Howson holds a B.S. in Chemical Engineering from the Technion in Israel, an M.B.A from Columbia University, and an M.S. from City College of New York. |
Denise Pollard-Knight |
Dr. Denise Pollard-Knight, Ph.D., is Independent Director of Idenix Pharmaceuticals Inc. Dr. Pollard-Knight has served as managing partner of Phase 4 Ventures since December 2010. Phase 4 Ventures manages funds on behalf of Nomura European Investments and Harbourvest. From April 2004 to December 2010, Dr. Pollard-Knight was head of Nomura Phase4 Ventures, an affiliate of Nomura International plc, a Japanese financial institution. From January 1999 to March 2004, Dr. Pollard-Knight served as head of Healthcare Private Equity at Nomura International plc. From January 1997 to January 1999, Dr. Pollard-Knight was a member of Rothschild Asset Management Ltd., an investment management firm. Dr. Pollard-Knight previously served as a director of Viacell and was a member of the Audit Committee. Dr. Pollard-Knight holds a Ph.D. and BSc (Hons) from the University of Birmingham in England. Dr. Pollard-Knight completed postdoctorate work as a Fulbright Scholar at the University of California, Berkeley. |
Michael Wyzga |
Mr. Michael S. Wyzga is Independent Director of Idenix Pharmaceuticals Inc., since March 01, 2012. Mr. Wyzga has served since December 2011 as the president and chief executive officer and as a member of the board of directors of Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a global biotechnology company. Mr. Wyzga joined Genzyme in February 1998 and most recently served as executive vice president, finance from May 2003 until November 2011 and as chief financial officer from July 1999 until November 2011. Mr. Wyzga received a B.S. from Suffolk University and an M.B.A. from Providence College. |
Teri Dahlman |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Thomas Hodgson |
-- |
Ronald Renaud |
1,383,760 |
Daniella Beckman |
501,542 |
David Standring |
738,193 |
Douglas Mayers |
680,578 |
Maria Stahl |
573,723 |
Paul Fanning |
-- |
Wayne Hockmeyer |
-- |
Tamar Howson |
-- |
Denise Pollard-Knight |
-- |
Michael Wyzga |
-- |
Teri Dahlman |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Thomas Hodgson |
0 | 0 |
Ronald Renaud |
0 | 0 |
Daniella Beckman |
0 | 0 |
David Standring |
15,000 | 12,900 |
Douglas Mayers |
0 | 0 |
Maria Stahl |
0 | 0 |
Paul Fanning |
0 | 0 |
Wayne Hockmeyer |
0 | 0 |
Tamar Howson |
0 | 0 |
Denise Pollard-Knight |
0 | 0 |
Michael Wyzga |
0 | 0 |
Teri Dahlman |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
RENAUD RONALD C JR |
35,000 | $2.96 |
RENAUD RONALD C JR |
39,990 | $2.41 |
FANNING PAUL J |
30,000 | $11.04 |
FANNING PAUL J |
30,000 | $2.41 |
NOVARTIS AG |
427 | $2.97 |
NOVARTIS AG |
883 | $5.79 |
NOVARTIS AG |
4,336 | $3.17 |
NOVARTIS AG |
493 | $6.52 |
NOVARTIS AG |
232 | $3.04 |
NOVARTIS AG |
35,735 | $2.41 |
NOVARTIS AG |
2,493 | $2.56 |
NOVARTIS AG |
39 | $5.10 |
NOVARTIS AG |
2,133 | $7.39 |
NOVARTIS AG |
997 | $2.69 |
NOVARTIS AG |
436 | $5.80 |
NOVARTIS AG |
3,093 | $3.79 |
NOVARTIS AG |
997 | $2.78 |
NOVARTIS AG |
366 | $2.47 |
NOVARTIS AG |
3,117 | $2.90 |
NOVARTIS AG |
8,960 | $2.96 |
NOVARTIS AG |
1,321 | $2.85 |
NOVARTIS AG |
7,402 | $5.46 |
NOVARTIS AG |
11,433 | $5.11 |
NOVARTIS AG |
6,476 | $2.96 |
NOVARTIS AG |
11,236 | $2.41 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
